Development of new cancer therapeutic agents targeting mitosis.

abstract：:Despite advances in supportive care, septic shock remains a major cause of morbidity and mortality. With the identification of the systemic inflammatory response as a major component in the pathogenesis of the septic shock syndrome, much of the recent work has focused on modulating this response. This includes antiend...

journal_title：Expert opinion on investigational drugs

authors： Sharma VK,Dellinger RP

更新日期：2003-02-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease is the leading cause of death worldwide, accounting for 30% of all deaths, with elevated blood pressure probably the most important modifiable risk factor. Worldwide, elevated blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all annual deaths. New ...

journal_title：Expert opinion on investigational drugs

authors： Segura J,Salazar J,Ruilope LM

更新日期：2013-07-01 00:00:00

abstract：:Zolmitriptan is a new oral acute treatment for migraine. It is a selective and potent agonist at the serotonin (5-HT)(1B/1D) receptor and was developed to improve on the oral bioavailability, tissue selectivity and CNS penetration of earlier compounds. Animal studies confirmed that these objectives had been attained. ...

journal_title：Expert opinion on investigational drugs

authors： Rolan PE,Martin GR

更新日期：1998-04-01 00:00:00

abstract：:Inhibiting the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) has an established role in the treatment of advanced non-small cell lung cancer. The first-generation EGFR inhibitors erlotinib and gefitinib have been approved for treatment in the second- and third-line setting. Second-generation ...

journal_title：Expert opinion on investigational drugs

authors： Mukherji D,Spicer J

更新日期：2009-03-01 00:00:00

abstract：:The outcome of patients with gastrointestinal stromal tumors has been dramatically improved by therapy with imatinib mesilate (imatinib mesylate), a KIT and platelet-derived growth factor (PDGFR) tyrosine kinase inhibitor. Unfortunately, the majority of patients eventually experience disease progression due to drug re...

journal_title：Expert opinion on investigational drugs

authors： Sankhala KK,Papadopoulos KP

更新日期：2007-10-01 00:00:00

abstract：INTRODUCTION:Because of the central role of the mammalian target of rapamycin (mTOR) pathway in the control and distribution of signals essential for mRNA translation of mitogenic genes and generation of oncogenic proteins, effective targeting of mTOR remains a major goal in medical oncology. AREAS COVERED:This articl...

journal_title：Expert opinion on investigational drugs

authors： Nelson V,Altman JK,Platanias LC

更新日期：2013-06-01 00:00:00

abstract：:Introduction: The armamentarium of antileishmanial drugs is small. It is further being threatened by the development of resistance and decreasing sensitivity to the available drugs. The development of newer drugs is sorely needed. Areas covered: The authors have based their review on a literature search performed usin...

journal_title：Expert opinion on investigational drugs

authors： Sundar S,Chakravarty J

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Glioblastoma is a primary brain tumor with a poor prognosis despite multimodal therapy including surgery, radiotherapy and alkylating chemotherapy. Novel therapeutic options are therefore urgently needed; however, there have been various drug failures in late-stage clinical development. The proteasome repr...

journal_title：Expert opinion on investigational drugs

authors： Roth P,Mason WP,Richardson PG,Weller M

更新日期：2020-10-01 00:00:00

abstract：:CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2001-06-01 00:00:00

abstract：:Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

journal_title：Expert opinion on investigational drugs

authors： Kreitman RJ

更新日期：1998-09-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Irritable bowel syndrome (IBS) represents one of the most common gastrointestinal disorders, with the diarrhea-predominant form (D-IBS) representing an area of high unmet medical need. One difficulty in identifying suitable treatments for IBS is that although there are animal models for the comp...

journal_title：Expert opinion on investigational drugs

authors： Mangel AW,Williams VS

更新日期：2010-10-01 00:00:00

abstract：:A disintegrin and metalloproteases (ADAMs) are zinc-dependent trans-membrane metalloproteases that shed the extracellular domains of membrane-bound growth factors, cytokines and receptors. Key functions of ADAMs have emerged in ErbB signalling pathways as being sheddases for multiple ErbB ligands. As the ErbB pathway ...

journal_title：Expert opinion on investigational drugs

authors： Zhou BB,Fridman JS,Liu X,Friedman SM,Newton RC,Scherle PA

更新日期：2005-06-01 00:00:00

abstract：INTRODUCTION:The introduction of therapy with tumor necrosis factor antagonists (aTNF) was a cornerstone of treatment modalities in patients with ankylosing spondylitis (AS). After > 10 years of using aTNF, the introduction of aTNF therapy was a major step forward in the medical management of patients with spondyloarth...

journal_title：Expert opinion on investigational drugs

authors： Braun J,Baraliakos X,Heldmann F,Kiltz U

更新日期：2014-05-01 00:00:00

abstract：INTRODUCTION:Axial spondyloarthritis (AxS pA) is a chronic inflammatory disease for which, until recently, there were no valid therapeutic alternatives to TNF-α blocking agents. This unmet clinical need led to explore several therapeutic targets, from proinflammatory cytokines to intracellular signaling systems. The re...

journal_title：Expert opinion on investigational drugs

authors： Clavel G,Boissier MC,Sigaux J,Semerano L

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:With 170 million people infected worldwide and an inadequate current standard of care, hepatitis C virus (HCV) infection represents a major unmet medical need. Multiple companies are working on the discovery and development of specific HCV antiviral drugs, including inhibitors of HCV polymerase, protease and...

journal_title：Expert opinion on investigational drugs

authors： Koev G,Kati W

更新日期：2008-03-01 00:00:00

abstract：INTRODUCTION:Gut-specific homing is mainly mediated by the expression of MAdCAM-1 on endothelial cells. An increase in MAdCAM-1 expression has been shown in patients with inflammatory bowel disease (IBD). Areas covered: PF-00547659 is a fully human monoclonal antibody (mAb) toward MAdCAM-1 on endothelial cells, blockin...

journal_title：Expert opinion on investigational drugs

authors： Allocca M,Gilardi D,Fiorino G,Furfaro F,Argollo M,Peyrin-Biroulet L,Danese S

更新日期：2018-07-01 00:00:00

abstract：INTRODUCTION:Fibroblast growth factor receptors (FGFR 1-4) are a highly conserved family of receptor tyrosine kinases, involved in several physiological processes. Genetic aberrations of FGFRs and their ligands, fibroblast growth factors (FGFs) are involved in several pathological processes including cancer. The FGF-FG...

journal_title：Expert opinion on investigational drugs

authors： Chandana SR,Babiker HM,Mahadevan D

更新日期：2020-12-01 00:00:00

abstract：:Insulin-sensitizing thiazolidinediones (TZDs) correct a root cause of type 2 diabetes and potentially other diseases of metabolic dysfunction, including conditions ranging from oncologic, inflammatory, and neurodegenerative diseases. Importantly, compounds with this mode of action can modify disease progression, as op...

journal_title：Expert opinion on investigational drugs

authors： Colca JR,Tanis SP,McDonald WG,Kletzien RF

更新日期：2014-01-01 00:00:00

abstract：:Myocardial protection through pharmacological approaches represents a large therapeutic challenge and is an important therapeutic strategy in patients with coronary artery disease, particularly after myocardial infarction. Extensive animal experiments have repeatedly demonstrated the efficacy of sodium-hydrogen exchan...

journal_title：Expert opinion on investigational drugs

authors： Karmazyn M

更新日期：2000-05-01 00:00:00

abstract：:Colorectal cancer is one of the most common cancers worldwide. Through well-designed clinical trials, advances have been made in the treatment of localised and advanced colorectal cancer. It has been established that 6 months of 5-fluorouracil-based chemotherapy will improve overall survival in patients with stage III...

journal_title：Expert opinion on investigational drugs

authors： Mulcahy MF,Benson AB 3rd

更新日期：2002-06-01 00:00:00

abstract：:Type 2 diabetes is a chronic metabolic disease that adversely affects both the quality and longevity of life. The disease is characterised by elevated blood glucose (hyperglycaemia) that is associated with microvascular complications and increased macrovascular risk. Existing oral agents, either alone or in combinatio...

journal_title：Expert opinion on investigational drugs

authors： Coghlan M,Leighton B

更新日期：2008-02-01 00:00:00

abstract：BACKGROUND:Based partially on encouraging findings from preclinical models, interest has grown in therapeutic inhibition of NF-kappaB to limit inflammatory injury during sepsis. However, NF-kappaB also regulates protective responses, and predicting the net survival effects of such inhibition may be difficult. OBJECTIV...

journal_title：Expert opinion on investigational drugs

authors： Li X,Su J,Cui X,Li Y,Barochia A,Eichacker PQ

更新日期：2009-08-01 00:00:00

abstract：:There are several reasons to believe that agents that augment cAMP-mediated signalling in cardiac myocytes should have beneficial effects in patients with heart failure. However, clinical trials of first-generation cyclic nucleotide phosphodiesterase (PDE3) inhibitors, which raise cAMP content by blocking its hydrolys...

journal_title：Expert opinion on investigational drugs

authors： Movsesian MA

更新日期：2000-05-01 00:00:00

abstract：BACKGROUND:Microtubule stabilizing agents such as taxanes are an integral part of therapy for multiple solid tumors. However, due to limitations of these agents, newer more effective cytotoxic agents are necessary. Ixabepilone, an epothilone B analog, is a novel microtubule stabilizing agent. OBJECTIVE:This review pro...

journal_title：Expert opinion on investigational drugs

authors： Denduluri N,Swain SM

更新日期：2008-03-01 00:00:00

abstract：:This review highlights some important advances that have taken place in cannabinoid research over the last four years. It focuses on novel ligands that are of interest either as experimental tools or as lead compounds for therapeutic agents and possible clinical applications for some of these ligands. The molecular ta...

journal_title：Expert opinion on investigational drugs

authors： Pertwee RG

更新日期：2000-07-01 00:00:00

abstract：:Toll-like receptors (TLRs) form a family of pattern recognition receptors that have emerged as key mediators of innate immunity. These receptors sense invading microbes and initiate the immune response. TLR-mediated inflammation is an important pathogenic link between innate immunity and a diverse panel of clinical di...

journal_title：Expert opinion on investigational drugs

authors： Földes G,von Haehling S,Anker SD

更新日期：2006-08-01 00:00:00

abstract：INTRODUCTION:Chagas disease treatment relies on the lengthy administration of benznidazole and/or nifurtimox, which have frequent toxicity associated. The disease, caused by the parasite Trypanosoma cruzi, is mostly diagnosed at its chronic phase when life-threatening symptomatology manifest in approximately 30% of tho...

journal_title：Expert opinion on investigational drugs

authors： Martínez-Peinado N,Cortes-Serra N,Losada-Galvan I,Alonso-Vega C,Urbina JA,Rodríguez A,VandeBerg JL,Pinazo MJ,Gascon J,Alonso-Padilla J

更新日期：2020-09-01 00:00:00

abstract：INTRODUCTION:Obesity is a major health threat in the Western world because of its high incidence and prevalence, and its association with metabolic and cardiovascular disease as well as cancer. The reduction of food intake in obese patients can be achieved only transiently (generally for no longer than 6 months), in th...

journal_title：Expert opinion on investigational drugs

authors： Folli F,Guardado Mendoza R

更新日期：2011-12-01 00:00:00

abstract：:New therapies targeting critical elements of the cell cycle open novel and attractive avenues for the treatment of cancer patients. At present, the number of clinical trials that are registered with the European Organization for Research and Treatment of Cancer (EORTC) and with the US National Cancer Institute, which ...

journal_title：Expert opinion on investigational drugs

authors： Berg T,Bug G,Ottmann OG,Strebhardt K

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Potent new drugs against multidrug-resistant Gram-negative bacteria, namely Pseudomonas aeruginosa and Acinetobacter spp. and pan-drug-resistant Klebsiella pneumoniae, which constitute an increasing medical threat, are almost absent from the future pharmaceutical pipeline. OBJECTIVE:This drug evaluation foc...

journal_title：Expert opinion on investigational drugs

authors： Poulakou G,Giamarellou H

更新日期：2008-05-01 00:00:00